{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:41:03Z","timestamp":1780605663579,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,22]]},"DOI":"10.7759\/cureus.86547","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T18:38:49Z","timestamp":1750617529000},"source":"Crossref","is-referenced-by-count":1,"title":["The Identification and Challenges of Dopamine Dysregulation Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Andrew","family":"Sulaiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idris","family":"Leppla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00529-5","article-title":"Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? The","volume":"2","author":"Lawrence AD","year":"2003","unstructured":"Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? The. Lancet Neurol. 2003, 2:595-604. 10.1016\/S1474-4422(03)00529-5","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22898","article-title":"Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward","volume":"25","author":"Evans AH","year":"2010","unstructured":"Evans AH, Lawrence AD, Cresswell SA, Katzenschlager R, Lees AJ. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord. 2010, 25:867-76. 10.1002\/mds.22898","journal-title":"Mov Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni G","year":"2000","unstructured":"Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000, 68:423-8. 10.1136\/jnnp.68.4.423","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O'Sullivan SS","year":"2009","unstructured":"O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs. 2009, 23:157-70. 10.2165\/00023210-200923020-00005","journal-title":"CNS Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb05525.x","article-title":"Iron supplements: a common cause of drug interactions","volume":"31","author":"Campbell NR","year":"1991","unstructured":"Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol. 1991, 31:251-5. 10.1111\/j.1365-2125.1991.tb05525.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"Diagnostic and Statistical Manual of Mental Disorders (5th ed.)","year":"2013","unstructured":"Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Association, Washington, DC; 2013. 10.1176\/appi.books.9780890425596"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315985","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases","volume":"88","author":"Warren N","year":"2017","unstructured":"Warren N, O'Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson's disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017, 88:1060-4. 10.1136\/jnnp-2017-315985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1039856219839476","article-title":"Dopamine dysregulation syndrome in non-Parkinson's disease patients: a systematic review","volume":"27","author":"Cartoon J","year":"2019","unstructured":"Cartoon J, Ramalingam J. Dopamine dysregulation syndrome in non-Parkinson's disease patients: a systematic review. Australas Psychiatry. 2019, 27:456-61. 10.1177\/1039856219839476","journal-title":"Australas Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome","volume":"85","author":"Cilia R","year":"2014","unstructured":"Cilia R, Siri C, Canesi M, et al.. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014, 85:311-8. 10.1136\/jnnp-2012-303988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6669-1","article-title":"Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease","volume":"260","author":"Sriram A","year":"2013","unstructured":"Sriram A, Ward HE, Hassan A, et al.. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol. 2013, 260:521-7. 10.1007\/s00415-012-6669-1","journal-title":"J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05237-8","article-title":"New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease","volume":"42","author":"Grassi G","year":"2021","unstructured":"Grassi G, Albani G, Terenzi F, Razzolini L, Ramat S. New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease. Neurol Sci. 2021, 42:2673-82. 10.1007\/s10072-021-05237-8","journal-title":"Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.13060126","article-title":"Successful treatment of dopamine dysregulation syndrome with valproic acid","volume":"26","author":"Epstein J","year":"2014","unstructured":"Epstein J, Madiedo CJ, Lai L, Hayes MT. Successful treatment of dopamine dysregulation syndrome with valproic acid. J Neuropsychiatry Clin Neurosci. 2014, 26:E3. 10.1176\/appi.neuropsych.13060126","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375748-the-identification-and-challenges-of-dopamine-dysregulation-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T18:38:50Z","timestamp":1750617530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375748-the-identification-and-challenges-of-dopamine-dysregulation-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.86547","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,22]]}}}